Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc.
Your view on INBX
Overview
What the company does, where it operates, and who runs it.
About Inhibrx Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Paul Lappe
- Headquarters
- 11025 North Torrey Pines Road, La Jolla, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mark Paul Lappe
- Headquarters
- 11025 North Torrey Pines Road, La Jolla, CA, US
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.
The company was incorporated in 2024 and is based in La Jolla, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Inhibrx Biosciences, Inc., and the rating behind it. INBX last traded at $109.27; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Inhibrx Biosciences, Inc.. Starting points for Inhibrx Biosciences, Inc.: EPS -$8.82, beta 3.67 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Inhibrx Biosciences, Inc.. Inhibrx Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Inhibrx Biosciences, Inc.. Trailing twelve-month EPS for Inhibrx Biosciences, Inc. stands at -$8.82. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Inhibrx Biosciences, Inc.. Inhibrx Biosciences, Inc. has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Inhibrx Biosciences, Inc. valued side by side against its closest peers. Inhibrx Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Inhibrx Biosciences, Inc., and how their positions are changing. At a $1.60B market value, institutional positions materially move Inhibrx Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Inhibrx Biosciences, Inc. executives and directors. Shares of Inhibrx Biosciences, Inc. have traded between $10.80 and $86.64 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Inhibrx Biosciences, Inc.. Inhibrx Biosciences, Inc. is a $1.60B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Inhibrx Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Inhibrx Biosciences, Inc.. Coverage tracks Inhibrx Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.